✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Affordable Blue Chip Stocks to Buy Now

Page 1 of 3

Blue-chip stocks are often associated with established businesses, strong financial positions, and the ability to generate returns over extended periods. However, even companies with substantial competitive advantages can become attractive at lower valuations when market uncertainty puts pressure on share prices. For long-term investors, the challenge is distinguishing businesses facing temporary setbacks from those whose earnings prospects have fundamentally deteriorated.

This difference has become particularly relevant in 2026. According to an October 30 Reuters report, the Nasdaq 100 was on course to lose more than $2 trillion in market capitalization during October as investors questioned whether substantial artificial intelligence investments would generate sufficient returns. The concerns extended beyond technology valuations to rising financing requirements and the sustainability of corporate spending. Gain more insight into the sector by accessing our complete list of the 10 Best Blue Chip Dividend Stocks to Buy Right Now here.

More recently, Reuters reported on November 11 that technology and AI-related stocks had retreated approximately 10% from their October peak. Although the pullback had attracted renewed buying interest, market indicators provided mixed evidence about whether the correction had ended. Gain insight into the AI sector through our list of the AI Stocks Dominating List of Biggest Winners.

For investors seeking long-term capital appreciation, these developments have brought greater attention to valuation alongside earnings growth. Established companies with profitable operations, competitive advantages, and substantial cash-generating capabilities can offer opportunities when their share prices decline. However, a low earnings multiple alone does not establish that a stock is undervalued, particularly when future earnings depend on unusually favorable industry conditions.

READ ALSO: 10 High P/E Stocks Under the 200-Day SMA

This makes forward price-to-earnings ratios useful as an initial screening measure rather than a complete investment thesis. When considered alongside financial performance, competitive positioning, and analysts’ expectations, they can help identify established businesses whose potential growth may not be fully reflected in their current valuations.

Our Methodology

To compile our list of the 10 best affordable blue-chip stocks to buy now, we screened blue-chip companies with a forward P/E below 15 and positive analyst upside potential (above 20%). These stocks are also popular among elite hedge funds, according to data derived from Insider Monkey’s database. The stocks are arranged in ascending order of their analyst upside.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

10 Best Affordable Blue Chip Stocks to Buy Now

10. Citigroup Inc. (NYSE:C)

Forward P/E: 9.39

Analyst Upside: 21.29%

Citigroup Inc. (NYSE: C) offers investors an opportunity to evaluate an established banking franchise undergoing a multiyear effort to improve returns and simplify its operations. The company’s investment case rests on various factors, with the most prominent being whether it can generate stronger profitability from its existing businesses while maintaining disciplined expense management.

Citigroup’s international Services business provides an important foundation for that effort. According to its third-quarter 2026 results, Services revenue increased 15% year over year and generated a return on tangible common equity of 31.2%. The segment benefits from institutional demand for payments, liquidity management, and securities services, activities that extend beyond traditional lending.

READ ALSO: 10 Unrivaled Stocks to Buy for the Next Decade

At the group level, return on tangible common equity reached 11.5%, up 350 basis points from a year ago. Management is targeting near-term goals of 11%–13% during 2027–2028, and a medium-term ambition of 14%–15%.

These targets provide measurable benchmarks for assessing the bank’s progress. However, achieving them will depend on execution, credit conditions, and expense discipline. Citigroup’s relatively low forward earnings multiple is relevant, but the sustainability of improving returns is more important than the multiple in isolation.

9. CVS Health Corporation (NYSE:CVS)

Forward P/E: 10.58

Analyst Upside: 24.36%

CVS Health Corporation (NYSE:CVS) offers a healthcare investment case centered on improving insurance profitability while maintaining its substantial pharmacy and healthcare services operations. Unlike companies whose earnings growth depends primarily on capital expenditure or technological innovation, CVS is working to improve returns across businesses already serving millions of customers.

One of the most important developments has been the recovery in its insurance operations. According to its third-quarter 2026 results, the Health Care Benefits segment generated $912 million in adjusted operating income, compared with $314 million a year earlier. Its medical benefit ratio improved from 92.8% to 91.3%, indicating that a smaller proportion of premium revenue was consumed by medical costs.

DON’T MISS: 10 Best Healthcare and Insurance Stocks To Buy Following the 2026 Democratic Midterm Sweep

The improvement contributed to management raising its full-year adjusted earnings guidance to at least $8.20 per share. CVS also increased its operating cash flow guidance to at least $15.5 billion.

However, healthcare costs remain elevated, and insurance margins are sensitive to medical utilization, reimbursement rates, and government policy. The longer-term investment opportunity depends on CVS maintaining better underwriting performance while supporting profitability across its pharmacy and healthcare services businesses.

Page 1 of 3